newsfilter
← Latest News
Business Wire·

Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual

- Study shows well-tolerated safety profile with no increased risk of CNV, complement regulation, reduction in inflammatory state and supports bi-monthly dosing Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company dev